Novel three-step pretargeted radioimmunotherapy offers safe, effective treatment
Researchers at Memorial Sloan Kettering Cancer Center in New York City and Massachusetts Institute of Technology in Boston have developed a new, three-step system that uses nuclear medicine to target and eliminate colorectal cancer. In this study with a mouse model, researchers achieved a 100-percent cure rate—without any treatment-related toxic effects. The study is reported in the November featured article in The Journal of Nuclear Medicine.
Until now, radioimmunotherapy (targeted therapy) of solid tumors using antibody-targeted radionuclides has had limited therapeutic success. “This research is novel because of the benchmarks reached by the treatment regimen, in terms of curative tumor doses, with non-toxic secondary radiation to the body’s normal tissues,” explains Steven M. Larson, MD, and Sarah Cheal, PhD, of Memorial Sloan Kettering Cancer Center. “The success in murine tumor models comes from the unique quality of the reagents developed by our group, and the reduction to practice methodology, including a theranostic approach that can be readily transferred, we believe, to patients.”
Theranostics, a term derived from therapy and diagnostics, is the use of a single agent to both diagnose and treat disease. The theranostic agent first finds the cancer cells, then destroys them, leaving healthy cells unharmed—minimizing side effects and improving quality of life for patients.
In this study, the glycoprotein A33 (GPA33), an antigen found on over 95 percent of primary and metastatic human colorectal cancers, was targeted with a bispecific antibody for A33 tumor antigen and a second antibody for a small-molecule radioactive hapten, a complex of lutetium-177 (177Lu) and S-2-(4-aminobenzyl)1,4,7,10-tetraazacyclododecane tetra-acetic acid (177Lu-DOTA-Bn).
The DOTA-pretargeted radioimmunotherapy (PRIT) strategy was tested on a mouse model. In randomly selected mice undergoing treatment, serial SPECT/CT imaging was used to monitor treatment response and calculate radiation-absorbed doses to tumors. All the DOTA-PRIT–treated animals tolerated the treatment well, and all 9 assessed mice had no trace of cancer remaining upon microscopic examination. There was also no detectable radiation damage to critical organs, including bone marrow and kidneys.
The 100-percent cure rate in the mouse model is a promising preliminary finding that suggests that anti-GPA33-DOTA-PRIT will be a potent radioimmunotherapy regimen for GPA33-positive colorectal cancer tumors in humans.
According to the Centers for Disease Control and Prevention, colorectal cancer is the third most common cancer affecting both men and women. Each year, approximately 140,000 new cases are diagnosed in the United States and 50,000 people die of the disease.
The applications of this nuclear medicine treatment protocol could extend to other cancers as well. Larson and Cheal state, “If clinically successful, our approach will expand the repertoire of effective treatments for oncologic patients. The system is designed as a ‘plug and play’ system, which allows for the use of many fine antibodies targeting human tumor antigens and is applicable, in principle, to virtually all solid and liquid tumors in man.” They add, “There is a huge unmet need in oncology, especially for the solid tumors, for curative treatments for advanced disease. This includes, colon, breast, pancreas, melanoma, lung, and esophageal, to name a few.”
The Latest on: Colorectal cancer
- Top stories in gastroenterology: Future of colorectal cancer screening, separating fact from fiction in a patient with Crohn’s diseaseon August 16, 2019 at 10:01 am
Among the top stories in gastroenterology last week were a video interview from GI Outlook 2019 that focused on the future of colorectal cancer screening and its viability in practice management and a ...
- Number of young people diagnosed with colorectal cancer on the riseon August 15, 2019 at 8:58 am
DENVER -- In Colorado, nearly 2,000 people will be diagnosed with colorectal cancer this year. Colorectal cancer is the third most commonly diagnosed cancer in the U.S. And while the overall death ...
- Exercise may extend the lives of advanced colorectal cancer patientson August 14, 2019 at 11:58 am
Aug. 14 (UPI) --Walking and other light workouts may help to extend the survival time of people with advanced colorectal cancer, new research shows. Those with the condition who performed ...
- Exercise associated with benefit to patients with advanced colorectal canceron August 14, 2019 at 7:44 am
Patients with metastatic colorectal cancer who engaged in moderate exercise while undergoing chemotherapy tended to have delayed progression of their disease and fewer severe side effects from ...
- Adjuvant chemotherapy does not provide survival benefits to elderly patients with stage II colon canceron August 14, 2019 at 2:36 am
To date, the effect of adjuvant chemotherapy after curative resection in patients with stage II colon cancer remains controversial. Still, little is known about the effects of adjuvant chemotherapy in ...
- At A CAGR of 1.9%, Colorectal Cancer Therapeutics Market is Projected To Achieve USD 9.8 Billion During Forecast Period 2017-2024on August 13, 2019 at 6:09 am
Aug 13, 2019 (AmericaNewsHour) -- Colorectal Cancer Therapeutics is a medical process which is used to treat cancer of colon and the rectum. This colorectal cancer starts either on colon or rectal and ...
- Colorectal Cancer Market By Current Industry Status,Growth Opportunities, Top Key Players, Target Audience And Forecast To 2025on August 13, 2019 at 4:32 am
Aug 13, 2019 (Garth Media via COMTEX) -- Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). The ...
- Move to western diets to blame for rise in colorectal cancer cases, oncologists sayon August 13, 2019 at 12:54 am
How Colorectal and colon cancer differ. [Courtesy] In the weeks after the succumbing of former Kibera MP Ken Okoth and former Bomet Governor Joyce Laboso to colon and colorectal cancers respectively, ...
- Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinomaon August 12, 2019 at 3:12 pm
Signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer (CRC). The aim of this study was to characterise the genomic alterations and outcomes of SRCC.
- Rain, lightning cancel 11th annual 500 run for colon cancer awarenesson August 11, 2019 at 4:00 pm
NIYAH: HEAVY RAINFALL, PUTTING A DAMPER ON THINGS SUNDAY MORNING. MORE THAN 600 PEOPLE WERE SUPPOSED TO PARTICIPATE IN A 5K RACE TO SPREAD AWARENESS ABOUT COLON CANCER, BUT -- >> UNFORTUNATELY, ...
via Google News and Bing News